Search

The future of glaucoma management: From sustained drug delivery to remote IOP monitoring

Glaucoma is a leading cause of irreversible vision loss worldwide, affecting millions around the globe [1]. Despite major advances in glaucoma treatment, complications of surgery and long-term disease management remain challenging due to poor adherence to topical medications, fluctuating intraocular...

IN FOCUS - Prevention and treatment of blindness worldwide: the story of ‘VISION 2020: The Right to Sight’

The story of blindness and efforts to prevent and treat it cannot be told without going back to the earliest recorded history of blindness. Trachoma was described in ancient Egypt, cataract surgery in India about the fifth century BC and...

Twenty-five years in retina

In the next of our articles celebrating 25 years of Eye News, the authors look at how the retina specialty has changed over this time and ask what the future might hold. Retinal disease management has benefited from great advances...

In conversation with Captain Gary Dyson

Captain Gary Dyson, Chief Pilot of the Orbis Flying Eye Hospital, spoke to Chris Henson about his 22-year stint flying the plane, its role at the cutting edge of aviation and medical technology, and how Orbis plan to continue to...

The International Centre for Eye Health: weaving the global threads together

The VISION 2020 LINKS & Networks Programme has been writing regular articles in Eye News about its capacity-strengthening activities in low- and middle-income countries (LMICs) for more than a decade. This, the first International Issue, is a landmark for Eye...

The past and the future for paediatric ophthalmology

The past 25 years have seen remarkable advances in clinical eye care for children in the UK. This has led to both improved outcomes and better patient and family experiences. There have been substantial changes to patient pathways, major advances...

A closer look at the new wave of glaucoma surgery – radical or old school?

Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...